About Us



Gaurav Shah MD

Gaurav Shah MD

Gaurav K. Shah, MD, is a retina specialist at The Retina Institute and Professor of Clinical Ophthalmology and Visual Sciences and Co-Director of Vitreoretinal Fellowship Program. He received his medical degree from the University Of Illinois College Of Medicine in Chicago. He completed his residency in ophthalmology at the University of Minnesota in Minneapolis followed by a retina fellowship at Wills Eye Institute in Philadelphia, Pennsylvania.

 

Dr Shah’s clinical and research interests include diabetic retinopathy, diabetic macular edema, age-related macular degeneration, and retinal detachments as well as the economics of retinal healthcare. He has a specific interest on Macular Surgery and Retinal Detachment repair with specific instrumentation design. He has been involved in several pivotal clinical trials including those investigating pegaptanib, ranibizumab, photodynamic therapy (PDT), and combination regimens consisting of PDT and bevacizumab. He is also an investigator for several phase II and phase III clinical trials for age-related macular degeneration, diabetic macular edema, retinal vein occlusion, dry macular degeneration, and new drug delivery devices and is currently the Principal Investigator for the CRAVE study. Dr Shah is a frequent presenter at national and international meetings and has authored 12 book chapters and more than 139 peer-reviewed articles. In addition, he is an elected member of the Retina Society, the Macula Society, American Society of Retina Specialists (ASRS) International Affairs Chair, the American Academy of Ophthalmology, OMIC and part of the ORBIS retina team. He is on the editorial board for Eye Net, OSLI and Review of Ophthalmology. In addition, he is a board examiner for ABO.  He also serves as Head of International Affairs for the ASRS.

Please refer to OMIC's Copyright and Disclaimer regarding the contents on this website

Leave a comment



Six reasons OMIC is the best choice for ophthalmologists in America.

Best at defending claims.

An ophthalmologist pays nearly half a million dollars in premiums over the course of a career. Premium paid is directly related to a carrier’s claims experience. OMIC has a higher win rate taking tough cases to trial, full consent to settle (no hammer) clause, and access to the best experts. OMIC pays 25% less per claim than other carriers. As a result, OMIC has consistently maintained lower base rates than multispecialty carriers in the U.S.

61864684